Latest Spark Therapeutics Stories
PHILADELPHIA, Dec. 31, 2014 /PRNewswire/ -- Spark Therapeutics announced today that it has filed a registration statement on Form S-1 with the U.S.
Company on track to report Phase 3 data in second half of 2015 PHILADELPHIA, Nov.
Company will draw on leaders' expertise in rare diseases, R&D and commercialization as it moves to complete development of its lead program in inherited blindness PHILADELPHIA, June
Gene therapy leader to advance its deep pipeline of rare disease programs including its lead Phase 3 product candidate for RPE65-related blindness PHILADELPHIA, May 27, 2014 /PRNewswire/
PHILADELPHIA, March 25, 2014 /PRNewswire/ -- Spark Therapeutics and Genable
Joseph La Barge and Carol Greve-Philips expand business operations PHILADELPHIA, Jan.
- Growing in low tufty patches.